<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01490060</url>
  </required_header>
  <id_info>
    <org_study_id>2011-0620</org_study_id>
    <secondary_id>NCI-2012-00011</secondary_id>
    <nct_id>NCT01490060</nct_id>
  </id_info>
  <brief_title>Fosaprepitant in Patients Receiving Ifosfamide-based Regimen</brief_title>
  <official_title>Evaluation of Fosaprepitant's Effect on Drug Metabolism in Sarcoma Patients Receiving Ifosfamide-based Multi-day Chemotherapy Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn how different doses of fosaprepitant may
      effect how ifosfamide-based chemotherapy is absorbed by the body. Researchers also want to
      learn if fosaprepitant can help to control or prevent delayed nausea and/or vomiting that may
      be caused by chemotherapy. The safety of this drug will also be studied.

      Fosaprepitant is designed to block the natural substance in the brain that causes nausea and
      vomiting. This may help to prevent and/or control nausea and vomiting caused by chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Groups:

      If you are found to be eligible to take part in this study, you will receive fosaprepitant
      during 21-day chemotherapy cycles. You will be randomly assigned (as in a toss of dice) to 1
      of 2 study groups, each with 2 divisions:

        -  If you are in Group A1, you will receive fosaprepitant on Day 1 of Cycle 1.

        -  If you are in Group A2, you will receive fosaprepitant on Day 1 of Cycle 2.

        -  If you are in Group B1, you will receive fosaprepitant on Days 1 and 4 of Cycle 1.

        -  If you are in Group B2, you will receive fosaprepitant on Days 1 and 4 Cycle 2.

      You and the study staff will know to which group and division you are assigned. Each time you
      receive the drug, you will receive it by vein over about 20-30 minutes.

      You will also receive the ifosfamide-based chemotherapy prescribed by your doctor, as well as
      standard drugs for preventing nausea and vomiting (such as ondansetron, lorazepam,
      diphenhydramine, and promethazine). You will sign a separate consent form that will describe
      these treatments in detail, along with their risks.

      You will receive dexamethasone before chemotherapy, every day for 5 days, to help prevent
      nausea and vomiting.

      Before each chemotherapy cycle, you will be given a study diary. Each day, you will record
      any side effects you may . You should bring your study diary to every study visit so the
      study staff can review it.

      Study Visits:

      Before each cycle that you receive fosaprepitant, the following tests and procedures will be
      performed:

        -  You will have a physical exam.

        -  Your vital signs, weight, and performance status will be recorded.

        -  You will fill out the same questionnaire you did at screening.

        -  You will be asked about any other drugs you may be taking. Be sure to tell the study
           doctor about all drugs (including vitamins, herbal products, and nutritional
           supplements), because some drugs/substances will cause side effects when taken at the
           same time as fosaprepitant.

        -  Blood (about 5 teaspoons) will be drawn for routine tests.

      Blood (about 1 teaspoon) will also be drawn 2 times each week during Cycles 1 and 2 for
      routine tests.

      Pharmacokinetic Testing:

      On Days 1 and 4 of Cycles 1 and 2 of chemotherapy, blood samples (about 2 teaspoons each
      time) will be drawn for pharmacokinetic (PK) testing, when possible. PK testing measures the
      amount of study drug in the body at different time points. The blood will be drawn before you
      receive ifosfamide, at the end of the infusion, and 4 more times in the 24 hours after the
      infusion.

      Length of Study:

      You may receive up to 6 cycles of chemotherapy (and up to 5 cycles of fosaprepitant). You
      will no longer be able to take the study drug if the disease gets worse or if intolerable
      side effects occur.

      Your participation on the study will be over once you have completed the end-of-study visit.

      End-of-Study Visit:

      About 3 weeks after your last dose of fosaprepitant, you will return for an end-of-study
      visit. At this visit, the following tests and procedures will be performed:

        -  You will have a physical exam.

        -  Your vital signs, weight, and performance status will be recorded.

        -  You will fill out the same questionnaire you did at screening.

        -  You will be asked about any other drugs you may be taking.

        -  Blood (about 5 teaspoons) will be drawn for routine tests.

      This is an investigational study. Fosaprepitant is FDA approved and commercially available in
      combination with other drugs for the prevention of nausea and vomiting that may be caused by
      chemotherapy. It is investigational to study how fosaprepitant may affect the drug levels of
      ifosfamide in the blood and how many doses should be given.

      Up to 36 patients will take part in this study. All will be enrolled at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response</measure>
    <time_frame>From Day 1 to Day 5 in two 21-days cycles (Cycle 1 and Cycle 2).</time_frame>
    <description>Complete response (CR) defined as: No emetic episodes and no rescue medications. This is a cross-over designed study, the outcomes by single dose, two doses and control cycles were evaluated by combining the results from both cycle 1 and cycle 2 according to the treatment received.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Sarcoma</condition>
  <condition>Chemotherapy-induced Nausea and Vomiting</condition>
  <condition>Effects of Chemotherapy</condition>
  <condition>Adverse Effects of Medical Drugs</condition>
  <arm_group>
    <arm_group_label>Single Dose Day 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1, Single Dose: Fosaprepitant 150 mg intravenous (IV) Day 1 of Cycle 1 or Day 1 of Cycle 2. Participants randomized to Group 1 (Fosaprepitant Cycle 1 + No Fosaprepitant Cycle 2); or Group 2 (No Fosaprepitant Cycle 1 and Fosaprepitant Cycle 2). Dexamethasone intravenously (IVPB) daily for 5 days (12 mg on day 1, and 8 mg on days 2-5) and 5HT3 receptor antagonist as standard of care 30 minutes prior to chemotherapy. Doxorubicin 25 mg/m^2/day IV continuous infusion for 72 hours on days 1, 2, and 3, completing infusion on day 4 (total dose: 75 mg/m^2) as part of AI Chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Two Doses Day 1 + Day 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 2, Two Doses: Fosaprepitant 150 mg IV Day 1 + Day 4 of Cycle 1 or Day 1 + Day 4 of Cycle 2. Participants randomized to Group 1 (Fosaprepitant Cycle 1 + No Fosaprepitant Cycle 2); or Group 2 (No Fosaprepitant Cycle 1 and Fosaprepitant Cycle 2). Dexamethasone intravenously (IVPB) daily for 5 days (12 mg on day 1, and 8 mg on days 2-5) and 5HT3 receptor antagonist as standard of care 30 minutes prior to chemotherapy. Doxorubicin 25 mg/m^2/day IV continuous infusion for 72 hours on days 1, 2, and 3, completing infusion on day 4 (total dose: 75 mg/m^2) as part of AI Chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosaprepitant</intervention_name>
    <description>150 mg administered intravenously, delivered in either single dose or two doses, on Day 1 for single dose and on Days 1 and 4 for two doses, varying between Cycle 1 or Cycle 2 depending upon randomization to arm.</description>
    <arm_group_label>Single Dose Day 1</arm_group_label>
    <arm_group_label>Two Doses Day 1 + Day 4</arm_group_label>
    <other_name>Fosaprepitant Dimeglumine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Intravenous push (IVPB) daily for 5 days (12 mg on day 1, and 8 mg on days 2-5)</description>
    <arm_group_label>Single Dose Day 1</arm_group_label>
    <arm_group_label>Two Doses Day 1 + Day 4</arm_group_label>
    <other_name>Dexamethasone acetate</other_name>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5HT3 receptor antagonist</intervention_name>
    <description>5HT3 receptor antagonist as standard of care 30 minutes prior to chemotherapy</description>
    <arm_group_label>Single Dose Day 1</arm_group_label>
    <arm_group_label>Two Doses Day 1 + Day 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide-based chemotherapy (AI)</intervention_name>
    <description>Doxorubicin + Mesna + + Ifosfamide + Vincristine, chemotherapy cycles repeated every 3-4 weeks for up to 6 cycles. Chemotherapy drugs listed separately, individual dosages, etc.</description>
    <arm_group_label>Single Dose Day 1</arm_group_label>
    <arm_group_label>Two Doses Day 1 + Day 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>25 mg/m^2/day IV continuous infusion for 72 hours on days 1, 2, and 3, completing infusion on day 4 (total dose: 75 mg/m^2) as part of AI Chemotherapy.</description>
    <arm_group_label>Single Dose Day 1</arm_group_label>
    <arm_group_label>Two Doses Day 1 + Day 4</arm_group_label>
    <other_name>Rubex</other_name>
    <other_name>Adriamycin</other_name>
    <other_name>Adriamycin RDF</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Doxorubicin Hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>Prior to ifosfamide (Day 1) - 500 mg/m^2 (20% of ifosfamide dose) given simultaneously with ifosfamide and then daily continuous infusion (Days 1-4 completing infusion on day 4) - 1,500 mg/m^2/day (60% of daily ifosfamide dose) for a total of 6 gm/m^2. The mesna infusion complete 24 hours after last dose of ifosfamide.</description>
    <arm_group_label>Single Dose Day 1</arm_group_label>
    <arm_group_label>Two Doses Day 1 + Day 4</arm_group_label>
    <other_name>Mesnex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>2.5 g/m^2 IV bolus over 3 hours on days 1, 2, 3, 4 (total dose: 10 g/m^2).</description>
    <arm_group_label>Single Dose Day 1</arm_group_label>
    <arm_group_label>Two Doses Day 1 + Day 4</arm_group_label>
    <other_name>Ifex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>2 mg IV by rapid infusion (Day 1) may be given to participants with sarcomas of small cell histology.</description>
    <arm_group_label>Single Dose Day 1</arm_group_label>
    <arm_group_label>Two Doses Day 1 + Day 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with sarcoma which is locally advanced, at high risk for relapse or
             metastatic for whom treatment with doxorubicin plus ifosfamide (AI) or AI and
             vincristine (VAI) is indicated.

          2. Must be 18-65 years of age.

          3. Male and Females of child bearing potential must use acceptable methods of birth
             control which include oral contraceptives, spermicide with either a condom, diaphragm
             or cervical cap, us of a intrauterine device (IUD) or abstinence.

          4. Adequate hematologic (ANC &gt;/= 1500/mm^3, platelet count &gt;/= 100,000/mm^3), renal
             (serum creatinine &lt;/= 1.5 mg/dL), hepatic (serum bilirubin count &lt;/= 1.5 x normal and
             SGOT or SGPT &lt;/= 3 x normal) functions.

          5. Karnofsky Performance Status &gt;/= 60%

          6. Signed informed consent form.

          7. Patients are required to read and understand English to comply with protocol
             requirements.

        Exclusion Criteria:

          1. Pregnant or lactating women.

          2. Patients with any co-morbid condition which renders patients at high risk of treatment
             complication.

          3. Known allergy to fosaprepitant or any of its active components.

          4. Patient has uncontrolled angina, congestive heart failure (New York Heart Association
             &gt; class II or known ejection fraction &lt; 40%), uncontrolled cardiac arrhythmia or
             hypertension, or acute myocardial infarction within 3 months.

          5. Patient has an active seizure disorder. (Patients with a previous history of seizure
             disorders will be eligible for the study, if they have had no evidence of seizure
             activity, and they have been free of antiseizure medication for the previous 5 years).

          6. Prior surgery or radiotherapy (RT) within 2 weeks of study entry.

          7. Psychological, social, familial, or geographical reasons that would prevent scheduled
             visits and follow-up.

          8. Patients receiving any medication for pre-existing nausea/vomiting will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saroj Vadhan-Raj, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-3722</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2011</study_first_submitted>
  <study_first_submitted_qc>December 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2011</study_first_posted>
  <results_first_submitted>March 20, 2015</results_first_submitted>
  <results_first_submitted_qc>May 15, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 3, 2015</results_first_posted>
  <last_update_submitted>March 11, 2016</last_update_submitted>
  <last_update_submitted_qc>March 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>fosaprepitant</keyword>
  <keyword>Ifosfamide-based Multi-day Chemotherapy</keyword>
  <keyword>Chemotherapy-induced nausea and vomiting</keyword>
  <keyword>CINV</keyword>
  <keyword>multi-day chemotherapy regimens</keyword>
  <keyword>antiemetics</keyword>
  <keyword>adverse effect</keyword>
  <keyword>doxorubicin plus ifosfamide</keyword>
  <keyword>AI</keyword>
  <keyword>AI and vincristine</keyword>
  <keyword>VAI</keyword>
  <keyword>aprepitant</keyword>
  <keyword>prevention</keyword>
  <keyword>nausea</keyword>
  <keyword>vomiting</keyword>
  <keyword>emetogenic chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Mesna</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: May 21, 2012 to January 23, 2014. All recruitment done at The University of Texas (UT) MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A: Single Dose, Group 1</title>
          <description>Fosaprepitant 150 mg intravenous (IV) Day 1 of Cycle 1 (Group 1). Participants Randomized to Group 1 (Fosaprepitant Cycle 1 + No Fosaprepitant Cycle 2). Dexamethasone IVPB daily for 5 days (12 mg on day 1, and 8 mg on days 2-5) and 5HT3 receptor antagonist as standard of care 30 min prior to chemotherapy. Doxorubicin 25 mg/m^2/day IV continuous infusion for 72 hrs on days 1, 2, and 3, completing infusion on day 4 (total dose: 75 mg/m^2). Mesna: Prior to ifosfamide (Day 1) - 500 mg/m^2 given simultaneously with ifosfamide and then daily CI (Days 1-4 completing infusion on day 4) – 1,500 mg/m^2/day for a total of 6 gm/m^2. The mesna infusion will complete 24 hrs after the last dose of ifosfamide. Ifosfamide: 2.5 g/m^2 IV bolus over 3 hrs on days 1, 2, 3, 4 (total dose: 10 g/m^2). Vincristine: 2 mg IV by rapid infusion (Day 1) may be given to participants with sarcomas of small cell histology.</description>
        </group>
        <group group_id="P2">
          <title>Arm A: Single Dose, Group 2</title>
          <description>Fosaprepitant 150 mg intravenous (IV) Day 1 of Cycle 2 (Group 2). Participants Randomized to Group 2 (No Fosaprepitant Cycle 1 + Fosaprepitant Cycle 2). Dexamethasone IVPB daily for 5 days (12 mg on day 1, and 8 mg on days 2-5) and 5HT3 receptor antagonist as standard of care 30 min prior to chemotherapy. Doxorubicin 25 mg/m^2/day IV continuous infusion for 72 hrs on days 1, 2, and 3, completing infusion on day 4 (total dose: 75 mg/m^2). Mesna: Prior to ifosfamide (Day 1) - 500 mg/m^2 given simultaneously with ifosfamide and then daily CI (Days 1-4 completing infusion on day 4) – 1,500 mg/m^2/day for a total of 6 gm/m^2. The mesna infusion will complete 24 hrs after the last dose of ifosfamide. Ifosfamide: 2.5 g/m^2 IV bolus over 3 hrs on days 1, 2, 3, 4 (total dose: 10 g/m^2). Vincristine: 2 mg IV by rapid infusion (Day 1) may be given to participants with sarcomas of small cell histology.</description>
        </group>
        <group group_id="P3">
          <title>Arm B: Two Doses, Group 1</title>
          <description>Fosaprepitant 150 mg IV Day 1 + Day 4 of Cycle 1 (Group 1). Participants Randomized to Group 1 (Fosaprepitant Cycle 1 + No Fosaprepitant Cycle 2). Dexamethasone IVPB daily for 5 days (12 mg on day 1, and 8 mg on days 2-5) and 5HT3 receptor antagonist as standard of care 30 min prior to chemotherapy. Doxorubicin 25 mg/m^2/day IV continuous infusion for 72 hrs on days 1, 2, and 3, completing infusion on day 4 (total dose: 75 mg/m^2). Mesna: Prior to ifosfamide (Day 1) - 500 mg/m^2 given simultaneously with ifosfamide and then daily CI (Days 1-4 completing infusion on day 4) – 1,500 mg/m^2/day for a total of 6 gm/m^2. The mesna infusion will complete 24 hrs after the last dose of ifosfamide. Ifosfamide: 2.5 g/m^2 IV bolus over 3 hrs on days 1, 2, 3, 4 (total dose: 10 g/m^2). Vincristine: 2 mg IV by rapid infusion (Day 1) may be given to participants with sarcomas of small cell histology.</description>
        </group>
        <group group_id="P4">
          <title>Arm B: Two Doses, Group 2</title>
          <description>Fosaprepitant 150 mg IV Day 1 + Day 4 of Cycle 2 (Group 2). Participants Randomized to Group 2 (No Fosaprepitant Cycle 1 + Fosaprepitant Cycle 2). Dexamethasone IVPB daily for 5 days (12 mg on day 1, and 8 mg on days 2-5) and 5HT3 receptor antagonist as standard of care 30 min prior to chemotherapy. Doxorubicin 25 mg/m^2/day IV continuous infusion for 72 hrs on days 1, 2, and 3, completing infusion on day 4 (total dose: 75 mg/m^2). Mesna: Prior to ifosfamide (Day 1) - 500 mg/m^2 given simultaneously with ifosfamide and then daily CI (Days 1-4 completing infusion on day 4) – 1,500 mg/m^2/day for a total of 6 gm/m^2. The mesna infusion will complete 24 hrs after the last dose of ifosfamide. Ifosfamide: 2.5 g/m^2 IV bolus over 3 hrs on days 1, 2, 3, 4 (total dose: 10 g/m^2). Vincristine: 2 mg IV by rapid infusion (Day 1) may be given to participants with sarcomas of small cell histology.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Cycle 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Change of Treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insurance Denied</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment at Another Facility</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Cycle 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Change of Treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event Related to Chemotherapy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A: Single Dose, Day 1</title>
          <description>Fosaprepitant 150 mg intravenous (IV) Day 1 of Cycle 1 (Group 1) or Day 1 of Cycle 2 (Group 2). Participants Randomized to Group 1 (Fosaprepitant Cycle 1 + No Fosaprepitant Cycle 2) or Group 2 (No Fosaprepitant Cycle 1 + Fosaprepitant Cycle 2).</description>
        </group>
        <group group_id="B2">
          <title>Arm B: Two Doses, Day 1 + Day 4</title>
          <description>Fosaprepitant 150 mg IV Day 1 + Day 4 of Cycle 1 (Group 1) or Day 1 + Day 4 of Cycle 2 (Group 2). Participants Randomized to Group 1 (Fosaprepitant Cycle 1 + No Fosaprepitant Cycle 2) or Group 2 (No Fosaprepitant Cycle 1 + Fosaprepitant Cycle 2).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Between 19 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complete Response</title>
        <description>Complete response (CR) defined as: No emetic episodes and no rescue medications. This is a cross-over designed study, the outcomes by single dose, two doses and control cycles were evaluated by combining the results from both cycle 1 and cycle 2 according to the treatment received.</description>
        <time_frame>From Day 1 to Day 5 in two 21-days cycles (Cycle 1 and Cycle 2).</time_frame>
        <population>Out of 40 eligible participants, 2 participants had change of treatment, 1 participant was noncompliant and 1 participant had an adverse event related to chemotherapy. 36 participants completed cycle 1 and cycle 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Cycle (Arm A/Arm B)</title>
            <description>Control cycle without fosaprepitant.</description>
          </group>
          <group group_id="O2">
            <title>Arm A: Single Dose, Day 1</title>
            <description>Fosaprepitant 150 mg intravenous (IV) Day 1 of Cycle 1 (Group 1) or Day 1 of Cycle 2 (Group 2). Participants Randomized to Group 1 (Fosaprepitant Cycle 1 + No Fosaprepitant Cycle 2) or Group 2 (No Fosaprepitant Cycle 1 + Fosaprepitant Cycle 2).</description>
          </group>
          <group group_id="O3">
            <title>Arm B: Two Doses, Day 1 + Day 4</title>
            <description>Fosaprepitant 150 mg IV Day 1 + Day 4 of Cycle 1 (Group 1) or Day 1 + Day 4 of Cycle 2 (Group 2). Participants Randomized to Group 1 (Fosaprepitant Cycle 1 + No Fosaprepitant Cycle 2) or Group 2 (No Fosaprepitant Cycle 1 + Fosaprepitant Cycle 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response</title>
          <description>Complete response (CR) defined as: No emetic episodes and no rescue medications. This is a cross-over designed study, the outcomes by single dose, two doses and control cycles were evaluated by combining the results from both cycle 1 and cycle 2 according to the treatment received.</description>
          <population>Out of 40 eligible participants, 2 participants had change of treatment, 1 participant was noncompliant and 1 participant had an adverse event related to chemotherapy. 36 participants completed cycle 1 and cycle 2.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) and Serious Adverse Events (SAEs) were assessed in two 21-days cycles (Cycle 1 and Cycle 2). Collection period: May 23, 2012 to June 11, 2014.</time_frame>
      <desc>Number of participants for different study groups are: 22 single dose, Arm A (11 from group 1, cycle 1 &amp; 11 from group 2, cycle 2); 17 two doses, Arm B (9 from group 1, cycle 1 &amp; 8 from group 2, cycle 2); 37 control cycle [Arm A: 21(12 from group 1, cycle 2 &amp; 11 from group 2,cycle 1); Arm B: 16(8 from group 1, cycle 2 &amp; 8 from group 2,cycle 1)].</desc>
      <group_list>
        <group group_id="E1">
          <title>Control Cycle (Arm A/Arm B)</title>
          <description>Control cycle without fosaprepitant.</description>
        </group>
        <group group_id="E2">
          <title>Arm A: Single Dose, Day 1</title>
          <description>Fosaprepitant 150 mg intravenous (IV) Day 1 of Cycle 1 (Group 1) or Day 1 of Cycle 2 (Group 2). Participants Randomized to Group 1 (Fosaprepitant Cycle 1 + No Fosaprepitant Cycle 2) or Group 2 (No Fosaprepitant Cycle 1 + Fosaprepitant Cycle 2).</description>
        </group>
        <group group_id="E3">
          <title>Arm B: Two Doses, Day 1 + Day 4</title>
          <description>Fosaprepitant 150 mg IV Day 1 + Day 4 of Cycle 1 (Group 1) or Day 1 + Day 4 of Cycle 2 (Group 2). Participants Randomized to Group 1 (Fosaprepitant Cycle 1 + No Fosaprepitant Cycle 2) or Group 2 (No Fosaprepitant Cycle 1 + Fosaprepitant Cycle 2).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE v4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenic Fever</sub_title>
                <description>Related to Myelosuppression from chemotherapy in the first 2 cycles.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE v4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Disorders</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="37"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="22"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="37"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="22"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="37"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="22"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="37"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="37"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="37"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Memory Impairment</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Saroj Vadhan-Raj, MD/Professor, Sarcoma Medical Oncology</name_or_title>
      <organization>University of Texas (UT) MD Anderson Cancer Center</organization>
      <phone>(713) 792-7966</phone>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

